Oppenheimer Asset Management Inc. Purchases 1,439 Shares of Insmed, Inc. $INSM

Oppenheimer Asset Management Inc. raised its position in shares of Insmed, Inc. (NASDAQ:INSM) by 7.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,374 shares of the biopharmaceutical company’s stock after acquiring an additional 1,439 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Insmed were worth $2,151,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Teachers Retirement System of The State of Kentucky bought a new stake in Insmed during the first quarter valued at about $975,000. Chung Wu Investment Group LLC bought a new stake in Insmed during the second quarter valued at about $173,000. OneDigital Investment Advisors LLC boosted its holdings in Insmed by 47.1% during the first quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company’s stock valued at $399,000 after acquiring an additional 1,673 shares during the period. Caxton Associates LLP bought a new stake in Insmed during the first quarter valued at about $441,000. Finally, Assenagon Asset Management S.A. boosted its holdings in Insmed by 84.5% during the second quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company’s stock valued at $7,387,000 after acquiring an additional 33,626 shares during the period.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research report on Wednesday, October 8th. TD Cowen upped their price objective on shares of Insmed from $154.00 to $193.00 and gave the company a “buy” rating in a research report on Thursday, October 2nd. Cantor Fitzgerald assumed coverage on shares of Insmed in a research report on Tuesday. They set an “overweight” rating and a $192.00 price objective for the company. Jefferies Financial Group upped their price objective on shares of Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, August 13th. Finally, Stifel Nicolaus upped their price objective on shares of Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, August 14th. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $161.59.

Insmed Stock Performance

NASDAQ:INSM opened at $166.95 on Thursday. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $168.21. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $35.29 billion, a PE ratio of -29.24 and a beta of 1.03. The firm has a 50-day moving average price of $149.63 and a 200 day moving average price of $110.68.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same period last year, the company earned ($1.94) EPS. The business’s revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. Research analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 6,865 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $128.40, for a total value of $881,466.00. Following the completion of the transaction, the chief executive officer owned 233,924 shares of the company’s stock, valued at $30,035,841.60. This represents a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the sale, the insider directly owned 36,461 shares of the company’s stock, valued at approximately $5,303,252.45. The trade was a 67.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 152,657 shares of company stock valued at $21,442,198. Corporate insiders own 3.00% of the company’s stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.